Clinical Trial Update: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) [Phase 3]

View source ↗

Summary

Phase 3 trial update for daprodustat (a prolyl hydroxylase inhibitor) in dialysis-related anemia shows completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 3 | Status: COMPLETED | Results posted: 2021-07-12